RGNX Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

15.710

Open

14.940

VWAP

14.94

Vol

2.76M

Mkt Cap

776.50M

Low

14.100

Amount

41.20M

EV/EBITDA(TTM)

--

Total Shares

51.70M

EV

793.51M

EV/OCF(TTM)

--

P/S(TTM)

8.75

REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address an array of diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). It is developing RGX-121 for the treatment of Mucopolysaccharidosis type II (MPS II), and RGX-111 to treat Mucopolysaccharidosis Type I.

Show More

Events Timeline

(ET)

2026-06-24

07:30:00

Regenxbio Completes Dosing in RGX-202 Confirmatory Study

2026-06-22 (ET)

2026-06-22

16:30:00

Nasdaq Declines Amid Weakness in Tech Stocks

2026-06-22

09:30:00

S&P 500 Futures Slightly Higher, Markets Cautious Start

2026-06-22

08:01:00

Regenxbio Aligns with FDA for Accelerated Navsunli Approval

2026-06-22

07:00:00

Regenxbio CEO: FDA Agrees to Reconsider Gene Therapy Application

2026-06-22

07:00:00

Regenxbio CEO: FDA Agrees to Reconsider Gene Therapy Application

News

PRnewswire

06-29PRnewswire

REGENXBIO Initiates Phase IIb/III Trial for Diabetic Retinopathy

Newsfilter

06-29Newsfilter

REGENXBIO Initiates Phase IIb/III Trial for Diabetic Retinopathy

seekingalpha

06-24seekingalpha

FDA's Regulatory Reversal Boosts Biotech Sector

PRnewswire

06-24PRnewswire

REGENXBIO Completes Dosing in RGX-202 Confirmatory Study

Newsfilter

06-24Newsfilter

REGENXBIO Completes Confirmatory Study for RGX-202 Ahead of Schedule

NASDAQ.COM

06-23NASDAQ.COM

Tenon Files S-1, Stock Surges 77.57%

7 Analyst Rating

Wall Street analysts forecast RGNX stock price to rise

7 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

19.00

Averages

29.71

High

45.00

Current: 0.000

Low

19.00

Averages

29.71

High

45.00

Baird

Baird

Outperform

maintain

$27 -> $32

AI Analysis

2026-06-23

Reason

Baird

Baird

Price Target

$27 -> $32

AI Analysis

2026-06-23

maintain

Outperform

Reason

Baird raised the firm's price target on Regenxbio to $32 from $27 and keeps an Outperform rating on the shares. The firm updated its model the reflect the FDA-aligned Hunter resubmission and favorable DMD read-through.

H.C. Wainwright

H.C. Wainwright

Buy

maintain

$26

2026-06-22

Reason

H.C. Wainwright

H.C. Wainwright

Price Target

$26

2026-06-22

maintain

Buy

Reason

After Regenxbio announced that it has aligned with the FDA regarding the resubmission of the Biologics License Application for Navsunli for Mucopolysaccharidosis II or Hunter syndrome, H.C. Wainwright noted that the company does not need to enroll additional patients or conduct additional studies. In the wake of this \"positive update,\" the firm reiterates its Buy rating and $26 price target on Regenxbio shares.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RGNX

Unlock Now

Valuation Metrics

The current forward P/E ratio for Regenxbio Inc (RGNX.O) is 0.00, compared to its 5-year average forward P/E of 2.03. For a more detailed relative valuation and DCF analysis to assess Regenxbio Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

2.03

Current PE

0.00

Overvalued PE

22.41

Undervalued PE

-18.35

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-1.21

Current EV/EBITDA

-0.23

Overvalued EV/EBITDA

13.36

Undervalued EV/EBITDA

-15.79

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

4.99

Current PS

2.77

Overvalued PS

7.95

Undervalued PS

2.03

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

give me a very bullish stock for today

Intellectia · 94 candidates

Price: >= $-100.00Rsi Category: moderatePrice Change Pct: >= $0.00Relative Vol: >= 1.50Moving Average Relationship: PriceAboveMA5, PriceAboveMA20, PriceAboveMA200Ema 5: >= -100Ema 20: >= -100Ema 60: >= -100Macd: positive, bullish

Ticker

Name

Market Cap$

Entera Bio Ltd

72.95M

Getty Images Holdings Inc

481.80M

Elite Express Holding Inc

11.92M

Eshallgo Inc

8.21M

GP-Act III Acquisition Corp

391.72M

GigaMedia Ltd

16.14M

what if I have $5000 to invest

Intellectia · 90 candidates

Region: USPrice: >= $-100.00Ema 20: >= -100News Driver: Positive

Ticker

Name

Market Cap$

Icecure Medical Ltd

17.96M

Uniqure NV

3.04B

Fathom Holdings Inc

36.39M

AstroNova Inc

219.65M

Allbirds Inc

48.26M

Euro Tech Holdings Company Ltd

11.64M

news about stocks that are below 10 dollar

Intellectia · 100 candidates

Region: USPrice: $1.00 - $10.00Relative Vol: >= 2List Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 2,000,000News Driver: Positive, Negative

Ticker

Name

Market Cap$

XWELL Inc

6.98M

Larimar Therapeutics Inc

494.39M

VS Media Holdings Ltd

5.06M

Evolent Health Inc

350.52M

Navitas Semiconductor Corp

2.27B

Sharplink Inc

1.46B

update list for stock prices between 5-50

Intellectia · 64 candidates

Price: $5.00 - $50.00Moving Average Relationship: PriceBelowMA20Week Price Change Pct: <= $-7.00Month Price Change Pct: <= $-10.00Monthly Average Dollar Volume: >= 800,000

Ticker

Name

Market Cap$

Venu Holding Corp

364.84M

Regenxbio Inc

698.09M

Anbio Biotechnology

2.89B

SMX (Security Matters) PLC

156.97M

Northrim BanCorp Inc

510.78M

Array Digital Infrastructure Inc

4.03B

Whales Holding RGNX

Voss Capital, LP

Redmile Group, LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is Regenxbio Inc (RGNX) stock price today?

The current price of RGNX is 15.02 USD — it has increased 1.28

What is Regenxbio Inc (RGNX)'s business?

REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address an array of diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). It is developing RGX-121 for the treatment of Mucopolysaccharidosis type II (MPS II), and RGX-111 to treat Mucopolysaccharidosis Type I.

What is the price predicton of RGNX Stock?

Wall Street analysts forecast RGNX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RGNX is29.71 USD with a low forecast of 19.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Regenxbio Inc (RGNX)'s revenue for the last quarter?

Regenxbio Inc revenue for the last quarter amounts to 6.39M USD, decreased -92.82

What is Regenxbio Inc (RGNX)'s earnings per share (EPS) for the last quarter?

Regenxbio Inc. EPS for the last quarter amounts to -1.72 USD, decreased -1533.33

How many employees does Regenxbio Inc (RGNX). have?

Regenxbio Inc (RGNX) has 371 emplpoyees as of July 08 2026.

What is Regenxbio Inc (RGNX) market cap?

Today RGNX has the market capitalization of 776.50M USD.